Publications by authors named "A Feizpour"
Article Synopsis
- Plasma phospho-tau 217 (pTau217) assays, when performed on the common Lumipulse-G® platform, can effectively identify Alzheimer's disease (AD) by analyzing β-amyloid (Aβ) status and tau staging in patients.
- In a study with 388 participants, pTau217 showed strong correlations with PET imaging results, achieving high accuracy rates in distinguishing between Aβ-negative and Aβ-positive individuals, as well as different stages of tau pathology.
- The findings suggest that the plasma pTau217 assay is a reliable tool for predicting who might benefit from anti-β-amyloid treatments, emphasizing its potential for broader clinical use in AD diagnostics.
Article Synopsis
- The study investigates the role of the frontopolar cortex in managing the balance between executing actions and inhibiting them in both humans and macaque monkeys.
- After conducting a stop-signal task, researchers found that damage to the frontopolar cortex in monkeys resulted in longer response times and reduced efficiency in adapting to errors, but did not affect their ability to inhibit actions.
- The findings suggest that while the frontopolar cortex is crucial for optimizing response execution, it does not significantly influence action inhibition capabilities.
Article Synopsis
- Plasma p-tau217 and Tau-PET are effective biomarkers for predicting cognitive decline in individuals without cognitive impairment, showing similar effectiveness in testing.
- A study with 1534 participants demonstrated that using a combination of both biomarkers provided better predictive power than using either one alone.
- Sequential testing of plasma p-tau217 followed by Tau-PET significantly reduces the number of participants needed in clinical trials for preclinical Alzheimer's disease, streamlining the research process.
Background: 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) regulates intracellular cortisol and its inhibition by the small molecule inhibitor, Xanamem™, may provide a disease-modifying strategy for Alzheimer's disease (AD). Animal models suggest a range of 30-60% enzyme inhibition may suffice to provide neuroprotection.
Objective: To determine the regional brain occupancy of 11β-HSD1 by Xanamem™ in cognitively normal participants (CN) and mild cognitive impairment (MCI)/mild AD patients to investigate potential dosing ranges for future efficacy studies.
Two-Year Prognostic Utility of Plasma p217+tau across the Alzheimer's Continuum.
J Prev Alzheimers Dis
November 2023
Background: Plasma p217+tau has shown high concordance with cerebrospinal fluid (CSF) and positron emission tomography (PET) measures of amyloid-β (Aβ) and tau in Alzheimer's Disease (AD). However, its association with longitudinal cognition and comparative performance to PET Aβ and tau in predicting cognitive decline are unknown.
Objectives: To evaluate whether p217+tau can predict the rate of cognitive decline observed over two-year average follow-up and compare this to prediction based on Aβ (18F-NAV4694) and tau (18F-MK6240) PET.